PMID- 35271882
OWN - NLM
STAT- MEDLINE
DCOM- 20220404
LR  - 20220405
IS  - 1879-0631 (Electronic)
IS  - 0024-3205 (Linking)
VI  - 297
DP  - 2022 May 15
TI  - Dendritic cell-based cancer immunotherapy in the era of immune checkpoint 
      inhibitors: From bench to bedside.
PG  - 120466
LID - S0024-3205(22)00166-7 [pii]
LID - 10.1016/j.lfs.2022.120466 [doi]
AB  - Dendritic cells (DCs) can present tumoral antigens to T-cells and stimulate 
      T-cell-mediated anti-tumoral immune responses. In addition to uptaking, 
      processing, and presenting tumoral antigens to T-cells, co-stimulatory signals 
      have to be established between DCs with T-cells to develop anti-tumoral immune 
      responses. However, most of the tumor-infiltrated immune cells are 
      immunosuppressive in the tumor microenvironment (TME), paving the way for immune 
      evasion of tumor cells. This immunosuppressive TME has also been implicated in 
      suppressing the DC-mediated anti-tumoral immune responses, as well. Various 
      factors, i.e., immunoregulatory cells, metabolic factors, tumor-derived 
      immunosuppressive factors, and inhibitory immune checkpoint molecules, have been 
      implicated in developing the immunosuppressive TME. Herein, we aimed to review 
      the biology of DCs in developing T-cell-mediated anti-tumoral immune responses, 
      the significance of immunoregulatory cells in the TME, metabolic barriers 
      contributing to DCs dysfunction in the TME, tumor-derived immunosuppressive 
      factors, and inhibitory immune checkpoint molecules in DC-based cell therapy 
      outcomes. With reviewing the ongoing clinical trials, we also proposed a novel 
      therapeutic strategy to increase the efficacy of DC-based cell therapy. Indeed, 
      the combination of DC-based cell therapy with monoclonal antibodies against novel 
      immune checkpoint molecules can be a promising strategy to increase the response 
      rate of patients with cancers.
CI  - Copyright (c) 2022 Elsevier Inc. All rights reserved.
FAU - Ghorbaninezhad, Farid
AU  - Ghorbaninezhad F
AD  - Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran; 
      Department of Immunology, Faculty of Medicine, Tabriz University of Medical 
      Sciences, Tabriz, Iran; Student Research Committee, Tabriz University of Medical 
      Sciences, Tabriz, Iran.
FAU - Asadzadeh, Zahra
AU  - Asadzadeh Z
AD  - Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
FAU - Masoumi, Javad
AU  - Masoumi J
AD  - Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
FAU - Mokhtarzadeh, Ahad
AU  - Mokhtarzadeh A
AD  - Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran; 
      Pharmaceutical Analysis Research Center, Tabriz University of Medical Sciences, 
      Tabriz, Iran.
FAU - Kazemi, Tohid
AU  - Kazemi T
AD  - Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran; 
      Department of Immunology, Faculty of Medicine, Tabriz University of Medical 
      Sciences, Tabriz, Iran.
FAU - Aghebati-Maleki, Leili
AU  - Aghebati-Maleki L
AD  - Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
FAU - Shotorbani, Siamak Sandoghchian
AU  - Shotorbani SS
AD  - Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran; 
      Department of Immunology, Faculty of Medicine, Tabriz University of Medical 
      Sciences, Tabriz, Iran.
FAU - Shadbad, Mahdi Abdoli
AU  - Shadbad MA
AD  - Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran.
FAU - Baghbanzadeh, Amir
AU  - Baghbanzadeh A
AD  - Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
FAU - Hemmat, Nima
AU  - Hemmat N
AD  - Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
FAU - Bakhshivand, Mohammad
AU  - Bakhshivand M
AD  - Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran; 
      Department of Immunology, Faculty of Medicine, Tabriz University of Medical 
      Sciences, Tabriz, Iran.
FAU - Baradaran, Behzad
AU  - Baradaran B
AD  - Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran; 
      Department of Immunology, Faculty of Medicine, Tabriz University of Medical 
      Sciences, Tabriz, Iran. Electronic address: baradaranb@tbzmed.ac.ir.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20220307
PL  - Netherlands
TA  - Life Sci
JT  - Life sciences
JID - 0375521
RN  - 0 (Immune Checkpoint Inhibitors)
SB  - IM
MH  - Dendritic Cells
MH  - Humans
MH  - *Immune Checkpoint Inhibitors/therapeutic use
MH  - Immunotherapy
MH  - *Neoplasms/metabolism
MH  - Tumor Microenvironment
OTO - NOTNLM
OT  - Cell therapy
OT  - Combinational therapy
OT  - Dendritic cell
OT  - Immune checkpoint
OT  - Immunotherapy
OT  - Tumor microenvironment
EDAT- 2022/03/11 06:00
MHDA- 2022/04/05 06:00
CRDT- 2022/03/10 20:12
PHST- 2021/12/29 00:00 [received]
PHST- 2022/03/02 00:00 [revised]
PHST- 2022/03/04 00:00 [accepted]
PHST- 2022/03/11 06:00 [pubmed]
PHST- 2022/04/05 06:00 [medline]
PHST- 2022/03/10 20:12 [entrez]
AID - S0024-3205(22)00166-7 [pii]
AID - 10.1016/j.lfs.2022.120466 [doi]
PST - ppublish
SO  - Life Sci. 2022 May 15;297:120466. doi: 10.1016/j.lfs.2022.120466. Epub 2022 Mar 
      7.